Proposing Bromo-Epi-Androsterone for Host-Directed Therapy Against Tuberculosis.

Area of Science:

• Immunology
• Pharmacology
• Infectious Diseases

Background:

• Tuberculosis (TB) remains a global health challenge, necessitating novel therapeutic strategies.
• Current treatments face challenges with drug resistance and latent infection management.
• Host-directed therapies offer a complementary approach to traditional antimycobacterial drugs.

Purpose of the Study:

• To evaluate Bromoepiandrosterone (BEA) as a potential host-directed therapy for active and latent tuberculosis.
• To investigate BEA's immunomodulatory effects and direct antimycobacterial properties.
• To assess BEA's efficacy in preclinical TB models.

Main Methods:

• BEA was administered in murine models of active and latent tuberculosis.
• Immunomodulatory effects were assessed by measuring cytokine profiles (e.g., IFN-γ, TNF-α, IL-4).
• Direct antimycobacterial activity was inferred, and synergy with standard anti-TB drugs was evaluated.

Main Results:

• BEA demonstrated potent immunomodulatory activity, promoting a Th1-skewed immune response.
• BEA inhibited 11β-hydroxysteroid dehydrogenase-1, reversing local immunosuppression.
• In vivo studies showed BEA halted bacterial growth, reduced inflammation, and enhanced bacterial clearance when combined with anti-TB drugs.

Conclusions:

• BEA is a promising candidate for host-directed therapy in TB, with dual immune-modulating and potential direct antimicrobial effects.
• BEA's ability to restore immune competency and synergize with existing drugs offers a novel strategy for drug-sensitive and drug-resistant TB.
• BEA may also play a role in managing latent TB by sustaining immune surveillance and preventing reactivation.